› Forums › General Melanoma Community › ASCO 2017 reports
- This topic has 9 replies, 8 voices, and was last updated 7 years, 11 months ago by
jbronicki.
- Post
-
- June 2, 2017 at 9:00 pm
Though it is with a heavy heart….I have begun plowing through what I think are the most pertinent ASCO abstracts for folks here. There are many sites through which you can read the abstracts and reports as well as see videos of presentations and discussions for yourself and I encourage you to do so! However, I will be putting abstracts grouped as they seem to read best, with pertinent background data if I have it, and my interpretation of the expert's jargon in red up on my blog. The rough topics I have made are: brain mets, ipi 3mg vs 10mg, outcomes after stopping immunotherapy, new combo's and meds (ipi with CD47, pembro with entinostat, nivo and anti-LAG-3), intralesionals, news for NRAS folks, and a few others.
Here is the first installment – posted today: ASCO 2017: Nivo or Ipi/Nivo combo in melanoma after progression on ipi or anti-PD-1
In honor of Jamie and Joshie….
I wish each of you well. Celeste
- Replies
-
-
- June 2, 2017 at 10:50 pm
thank you celeste…i was just starting to do asco googling…
But i have been unable to do much other than think about josh and jamie…..have been reading and rereading their respective melanoma journeys and just never thought this would be ending…..
it is so damn heartbreaking!.
But again, many thanks for all you do!!!!!
-
- June 2, 2017 at 11:50 pm
Thanks Celeste. Though I wasn't in the trial, I am grateful to be one of those ipi/nivo "salvage" patients.
-
- June 3, 2017 at 11:56 am
Thank you, Celeste!-
- June 3, 2017 at 1:03 pm
I was hoping you would see this, Michelle. It doesn't answer your recent conundrum directly…but I think you could extrapolate…that no matter the order of immunotherapy we participate in…after progressing on one…there is a chance of a response with another. I wish you well. c
- You must be logged in to reply to this topic.